Hapoalim Securities

Hapoalim Securities is terminating coverage of Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), Pfizer (NYSE: PFE), Acorda (NASDAQ: ACOR), Alkermes (NASDAQ: ALKS), Amarin (NASDAQ: AMRN), Amylin (NASDAQ: AMLN), Arena Pharmaceuticals (NASDAQ: ARNA), Auxilium (NASDAQ: AUXL),...

Hapoalim Securities announced it would be terminating coverage of a slew of pharmaceutical names due to an analyst departure. The names affected are Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY) Merck (NYSE: MRK) Pfizer (NYSE: PFE) Acorda (NASDAQ: ACOR), Alkermes (NASDAQ: ALKS) Amarin (NASDAQ:...

In a report released today, Hapoalim Securities commented on BioSpecifics (NASDAQ: BSTC). In the report, Hapoalim was bullish on the company. Hapoalim writes, “BioSpecifics reported 1Q11 EPS of $0.51 versus our $(0.06) estimate and the company anticipates that it will now be profitable on an...

Hapoalim Securities is reiterating its Sell rating and $1 price target on shares of MannKind (NASDAQ: MNKD). In a note to investors, Hapoalim writes, "MannKind announced that it has met with the FDA for an End-of-Review meeting for the Afrezza program and while the FDA seems to have agreed on the...

Hapoalim Securities is maintaining its Buy rating and raising its price target on shares of Alkermes (NASDAQ: ALKS) to $20 from $17 after the company did a deal with Elan (NYSE: ELN). In a note to clients, Hapoalim writes, "Alkermes and Elan Corporation announced that Alkermes will merge with Elan...

Ahead of First Solar's(NASDAQ: FSLR) 1Q11 earnings report, scheduled for after the close on Tuesday, May 3, Hapoalim Securities is lowering its 1Q11 estimates to reflect an industry‐wide slowdown amidst a harsh winter in Germany and regulatory dislocations in Italy in March and a shift in timing of...

Hapoalim Securities is raising its price target on shares of Amarin Corporation plc (NASDAQ: AMRN) to $23 from $12, after one of its drugs met Phase 3 expectations. In a note to clients, Hapoalim writes, "AMR101 met all primary and secondary endpoints in the Phase 3 ANCHOR trial, with...

Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) announced that Novartis (NYSE: NVS) has initiated a Phase 1 study “to evaluate a once-monthly injectable microsphere formulation and an aqueous crystals formulation of Fanapt,” Hapoalim Securities reports. “The pharmacokinetic study will likely be a three...

Hapoalim Securities is reiterating its Hold rating on Medivation (NASDAQ: MDVN). In a note to clients, Hapoalim writes, "Medivation announced that in the Phase 3 HORIZON Huntington's disease trial, Dimebon failed to achieve statistical significance for either of the co-primary endpoints....

Hapoalim Securities is out with a research note on the Valeant Pharmaceuticals deal for Cephalon (NASDAQ: CEPH). Yesterday Valeant offered $73 per share for Cephalon, but Hapoalim thinks it could go as high as $86. In a note to clients, Hapoalim writes, "Valeant is expecting $300 million or more...

Goldman Sachs is out with a research report this morning, where it reiterates its Buy rating on Amarin Corporation (NASDAQ: AMRN); it has a $12.00 price target on the stock. The HS analysts cited GlaxoSmithKline's announcement that it has settled with Apotex regarding the Lovaza (omega-3-acid...

Hapoalim Securities is upgrading shares of Targacept , Inc. (NASDAQ: TRGT) to Buy from Hold, and it has a $28 price target on shares. In a note to clients, Hapoalim writes, "While TC-5619 failed to meet the primary endpoint in a Phase 2 ADHD trial, secondary endpoints showed that TC-5619 is...

Hapoalim Securities has reported that Amarin Corporation's (NASDAQ: AMRN) 12 week Marine trial was positive. According to the report, “Amarin plans to submit an NDA for AMR101 to the FDA in 3Q11 for the indication studied in the MARINE trial (very high triglycerides) regardless of the outcome from...

Hapoalim Securities is out with a research report this morning, where it reiterates its Buy rating on Amarin Corporation (NASDAQ: AMRN); it has a $12.00 price target on the stock. The HS analysts cited the company's recent positive MARINE trial, which was a 12-week pivotal study to evaluate the...

Hapoalim Securities maintained its STR Holdings (NYSE: STRI) Buy rating and $26 price target in a research report. In the report, Hapoalim Securities states, "With revenues a bit light but margins holding firm, STRI reported a relatively in-line quarter with non-GAAP EPS of $0.39 coming in $0.02...